Health
GLP-1 drugmakers face dozens of US lawsuits over vision loss claims, report says
Al Jazeera reports that over 90 lawsuits claim GLP-1 medications caused a rare optic condition leading to vision loss.
The short version
- More than 90 lawsuits have been filed in US federal and state courts alleging GLP-1 diabetes and weight-loss drugs caused nonarteritic anterior ischemic optic neuropathy (NAION).[Al Jazeera]
- Lawsuits allege drugmakers failed to adequately warn patients about optic nerve damage that can lead to permanent vision loss.[Al Jazeera]
- Novo Nordisk denied the allegations as lacking merit, while scientific consensus remains unclear despite ongoing FDA investigations.[Al Jazeera]
Key facts
- Over 90 lawsuits have been filed against Novo Nordisk in New Jersey state court, alongside additional filings in Pennsylvania federal court.[Al Jazeera]
- The legal actions allege GLP-1 treatments cause NAION, an eye condition restricting blood flow to the optic nerve.[Al Jazeera]
- Novo Nordisk stated the suits lack merit, while Eli Lilly is reviewing potential risk data.[Al Jazeera]
- The FDA has been investigating potential links since 2024, but no official warning labels have been added in the US.[Al Jazeera]
What remains uncertain
- Whether GLP-1 medications directly cause NAION remains medically unproven, as company-funded trials show no increased risk while other observational studies indicate possible correlation.[Al Jazeera]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.